(Q53752984)

English

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Peter A. Fasching

5

object named as

P A Fasching

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

2

object named as

S Loibl

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

19

object named as

M Untch

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

author name string

B Gerber

1

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

H Eidtmann

3

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

M Rezai

4

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

H Tesch

6

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

H Eggemann

7

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

I Schrader

8

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

K Kittel

9

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

C Hanusch

10

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

R Kreienberg

11

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

C Solbach

12

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

C Jackisch

13

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

G Kunz

14

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

J U Blohmer

15

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

J Huober

16

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

M Hauschild

17

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

V Nekljudova

18

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

G von Minckwitz

20

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

German Breast Group Investigators

21

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

publication date

17 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

24

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

12

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

2978-2984

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

Triple-negative breast cancer: role of antiangiogenic agents

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Vascular proliferation is increased in basal-like breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT361

21 January 2018

Identifiers

10.1093/ANNONC/MDT361

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/24136883

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53752984&oldid=1245910169"